中文摘要：

目的研究进展期胃癌组织c-Kit表达及与相关指标和预后的关系,以探讨c-Kit能否作为胃癌分子靶向药物治疗靶点。方法采用免疫组化法研究了69例进展期胃癌组织标本的c-Kit表达及与MDR1和SSTR2的相关性,并对患者进行总生存期随访。结果进展期胃癌组织c-Kit阳性表达率为24.6%。c-Kit表达与患者性别、年龄、分期、分化及脉管和神经侵犯均无相关性。肿瘤组织c-Kit表达与MDR1（P=0.049）和SSTR2（P=0.013）表达有相关性。c-Kit表达阴性患者中位总生存期为13.8个月（95%CI 11.8～15.8个月）,c-Kit表达阳性患者中位总生存期为12.5个月（95%CI9.58～15.42个月,P=0.049）,两者差异具有统计学意义。ⅢA期病例c-Kit表达阴性患者中位总生存期为26.1个月（95%CI15.36～36.84个月）,c-Kit表达阳性患者中位总生存期仅为12.5个月（95%CI7.51～17.49个月,P=0.04）。结论 c-Kit可能是胃癌靶向酪氨酸激酶抑制剂使用靶点,但其相关机制有待体内外研究证实。

英文摘要：

Objective To explore the relationship between c-Kit expression and prognosis of advanced gastric cancer.Methods c-Kit expression was detected in tissue samples from 69cases of advanced gastric cancer by using immunochemistry,and its relationship with DMR1and SSTR2was analyzed.Survival data of all patients were analyzed by follow-up.Results The positive rate of c-Kit expression was 24.6%.c-Kit expression was not related to gender,age,stage,histological differentiation,and nerves and vessels involvement,but was related to MDR1（P= 0.049）and SSTR2（P=0.013）expression.The median overall survival of c-Kit negative patients was 13.8months（95%CI：11.8-15.8months）,while the median overall servival was 12.5months（95%CI：9.58-15.42months） in c-Kit positive patients,and the difference between the two groups was significant（P=0.049）.The median overall servival of c-Kit negative and positive patients at stageⅢA were 26.1months（95%CI：15.36-36.84months）and 12.5months（95% CI：7.51-17.49months）,and the difference was significant（P=0.04）.Conclusion c-Kit expression might be related to survival of patients with advanced gastric cancer and could be a potential therapeutic target,which should be confirmed by further investigation.